Authors

Latest:

Dr. Benson on Extensive Biopsies for Low-Risk Prostate Cancer

Mitchell Benson, MD, the Herbert and Florence Irving Professor at Columbia University Medical Center, New York-Presbyterian Hospital, discusses extensive biopsies in low-risk patients with prostate cancer.

Mitchell C. Benson MD, PhD

Latest:

Molecular Signature Distinguishes Indolent From Aggressive Prostate Cancer

Prostate cancer is one of the most common forms of cancer in older men, with more than 200,000 new diagnoses per year.

Mitchell R. Smith, MD, PhD

Latest:

Dr. Smith on the Patient Population of the ECOG-ACRIN E1411 Trial in MCL

Mitchell R. Smith, MD, PhD, discusses the patient population of the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.

Mitesh J. Borad, MD

Latest:

Dr Borad on the Initial Efficacy of RLY-4008 in FGFR2 Fusion–Positive Cholangiocarcinoma

Mitesh Borad, MD, key findings from the phase 1/2 ReFocus trial in FGFR2-altered cholangiocarcinoma.

Moben Mirza, MD

Latest:

Dr. Mirza on Hematuria and a Bladder Cancer Diagnosis

Moben Mirza, MD, assistant professor of urology at the University of Kansas Medical Center, discusses a study presented at the 2014 AUA Annual Meeting that evaluated gender and race variation in the workup of hematuria.

Mohamed Abazeed, MD, PhD

Latest:

Neural "Fingerprint" Enables Personalized SBRT Dose for Lung Cancer

A prognostic, deep-learning model developed by investigators at Cleveland Clinic’s Taussig Cancer Institute in Ohio and collaborators brings radiation oncology into the realm of personalized medicine.

Mohamed Abdel Khalek, MD

Latest:

Battling Burnout: Advice On Preventing and Dealing with Burnout in Your Future Career

A career in oncology can be a tremendously fulfilling and a meaningful venture. Oncologists care for the sick, advance medical science, and mentor the next generation of medical professionals.

Mohamed Akkad, MD

Latest:

Hemophagocytic Lymphohistiocytosis in a Patient With Nodular Lymphocyte–Predominant Hodgkin Lymphoma: A Case Report

This is the first case report of hemophagocytic lymphohistiocytosis complicating a nodular lymphocyte–predominant Hodgkin lymphoma in an adult treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.

Mohamed E. Abazeed, MD, PhD

Latest:

Cleveland Clinic Researchers Explore Genetic Landscape of Radiotherapeutic Resistance

Priyanka Gopal, MD, and Mohamed E. Abazeed, MD, PhD, discuss radiotherapy in the era of precision medicine.

Mohamed E. Salem, MD

Latest:

Dr. Salem on the Results of the MyPathway Trial in mCRC

Mohamed E. Salem, MD, a medical oncologist at Levine Cancer Institute, Atrium Health, discusses the results of the MyPathway trial in metastatic colorectal cancer (mCRC).

Mohamed E. Salem, MD, Georgetown University Hospital

Mohammad Jahanzeb, MD

Latest:

Dr. Jahanzeb on Immunotherapy in Oncogene-Driven NSCLC

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, at University of Miami Miller School of Medicine, discusses the use of immunotherapy in patients with oncogene-driven non–small cell lung cancer.

Mohammad Jahanzeb, MD, FACP, University of Miami, Miller School of Medicine

Mohammad Jahanzeb, MD, Sylvester Comprehensive Cancer Center

Mohammad Jahanzeb, MD, Univerity of Miami Miller School of Medicine

Mohammad Jahanzeb, MD, University of Miami Health System

Mohammad Maher

Latest:

Dr. Abdul Hay on Evaluation of Transplant Eligibility in ALL

Mohammad Maher Abdul Hay, MD, discusses the process of evaluating the eligibility of patients with acute lymphoblastic leukemia for transplant.

Mohammad Maher Abdul-Hay, MD

Latest:

Dr. Abdul-Hay on the Use of HCT-CI to Guide Transplant Eligibility in ALL

Mohammad Maher Abdul-Hay, MD, discusses the use of the Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) to guide transplant eligibility in acute lymphoblastic leukemia (ALL).

Mohammed Almubarak, MD

Latest:

Achieving Career Success in Academic Oncology

Academic oncologists have a critical role as opinion leaders and shape the future of cancer care by research and training future oncologists, residents, and medical students.

Mohammed Haseebuddin, MD

Latest:

Dr. Mohammed Haseebuddin on Expanding Role for Immunotherapy in RCC

Mohammed Haseebuddin, MD, a fellow in Urologic Oncology at Fox Chase Cancer Center, discuses why continued research into immunotherapy in clear cell renal cell carcinoma (RCC) is important, particularly in the adjuvant and neoadjuvant settings.